230 related articles for article (PubMed ID: 22149037)
1. Improving the outcomes: developing cancer therapeutics.
Utku N
Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
[TBL] [Abstract][Full Text] [Related]
2. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
6. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
8. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of treatment results with biological agents: is there a need for a new methodology?
Begent RH
J BUON; 2007 Sep; 12 Suppl 1():S53-8. PubMed ID: 17935278
[TBL] [Abstract][Full Text] [Related]
10. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
Marino P; Bertucci F; Gonçalves A; Seror V
Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
Dhani N; Siu LL
Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
Poste G
Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
[TBL] [Abstract][Full Text] [Related]
16. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
17. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?
Sargent D
Oncologist; 2010; 15 Suppl 1():19-23. PubMed ID: 20237213
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
19. [Molecular-target drug].
Sone S; Yano S; Nishioka Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
[TBL] [Abstract][Full Text] [Related]
20. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
